—Precise Generics =
Appetitive for innovation + Patient-Centric outcomes—
Company is offering generic drugs in Oncology while utilizing precision-based technology to increase the selection of which patients are more likely to respond to those who are less likely to respond. This will be provided to patients and also physicians as a tool to select the best treatment options for their patients.
— Leveraging a
BOOMING Market —
The annual revenue from precision medicine products is around $ 67 billion
Expected market revenue from precision medicine products worth $738.8 Billion by 2030
Significant increase in the FDA's drugs approval rates. The last five years averaged 46 approvals per year. This is more than double where it stood a decade ago
The global market for drug discovery technologies should grow from $69.8 billion in 2020 to $110.4 billion by 2025 with a compound annual growth rate (CAGR) of 9.6% for the period of 2020-2025
In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States
— We provide biopharma intelligence
solutions to our clients —
We look to create strong partnerships with pharmaceutical firms with registered APIs (active pharmaceutical ingredients) or clinical-trial phase drugs on the way to getting FDA approval. Our services assist with accelerating the regulatory process and increasing the chances of success. If you have an asset and want to boost the course of action, we can help you!